Page last updated: 2024-10-16

adenine and Chemical Dependence

adenine has been researched along with Chemical Dependence in 5 studies

Research Excerpts

ExcerptRelevanceReference
"Phase I, open-label, fixed-sequence, pharmacokinetic drug-drug interaction study."2.71Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. ( Berenson, CS; Booker, BM; Bullock, JM; Cloen, D; Coakley, DF; Flaherty, JF; Haas, CE; Kearney, BP; Liaw, S; Smith, PF; Yale, K, 2004)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Martin, M1
Vanichseni, S1
Suntharasamai, P1
Sangkum, U1
Mock, PA1
Leethochawalit, M1
Chiamwongpaet, S1
Gvetadze, RJ1
Kittimunkong, S1
Curlin, ME1
Worrajittanon, D1
McNicholl, JM1
Paxton, LA1
Choopanya, K1
Smith, PF1
Kearney, BP1
Liaw, S1
Cloen, D1
Bullock, JM1
Haas, CE1
Yale, K1
Booker, BM1
Berenson, CS1
Coakley, DF1
Flaherty, JF1
Chua, A1
Ford, N1
Wilson, D1
Cawthorne, P1
Franke, P1
Wang, T1
Nöthen, MM1
Knapp, M1
Neidt, H1
Albrecht, S1
Jahnes, E1
Propping, P1
Maier, W1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand[NCT00119106]Phase 2/Phase 32,413 participants (Actual)Interventional2005-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adherence to Study Drug/Placebo

Mean number of days that participants took study drug based on study drug diaries by study group. (NCT00119106)
Timeframe: Participants were asked about adherence at 3 month visits, up to 6.9 years.

Interventiondays (Mean)
Tenofovir84
Placebo84

Adverse Events

Number of Participants with adverse clinical events in tenofovir and placebo arms (NCT00119106)
Timeframe: Up to 6.9 years

Interventionparticipants (Number)
Tenofovir1098
Placebo1083

HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group

Plasma HIV RNA concentrations. (NCT00119106)
Timeframe: Among people who seroconverted, viral load was measured at month 1, 2, and every 4 months after HIV seroconversion

InterventionCopies/mL (Mean)
Tenofovir929829
Placebo120061

Number of Participants Reporting Injecting and Sharing Needles

"Number of Participants reporting injecting and sharing needles:~Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing." (NCT00119106)
Timeframe: Participants were asked about injecting and needle sharing behaviors at enrollment and every 3 month visit, up to 6.9 years

Interventionparticipants (Number)
Tenofovir58
Placebo59

Number of Participants With Tenofovir-associated Resistance Mutations.

Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups. (NCT00119106)
Timeframe: Specimens collected at the time of HIV seroconversion

InterventionParticipants (Count of Participants)
Tenofovir0
Placebo0

Number Participants Who Reported More Than One Sexual Partner at Baseline

Number of participants (NCT00119106)
Timeframe: At enrolment

InterventionParticipants (Count of Participants)
Tenofovir Group251
Placebo Group271

Rates of HIV Seroconversion

Kaplan Meier survival curve. (NCT00119106)
Timeframe: From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years

InterventionInfections/ 100 person-years (Number)
Tenofovir17
Placebo33

Renal Toxicity

Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities (NCT00119106)
Timeframe: Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years

Interventionparticipants (Number)
Tenofovir3
Placebo3

Trials

2 trials available for adenine and Chemical Dependence

ArticleYear
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle A

2014
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
    Pharmacotherapy, 2004, Volume: 24, Issue:8

    Topics: Adenine; Adult; Area Under Curve; Chromatography, High Pressure Liquid; Confidence Intervals; Drug I

2004

Other Studies

3 other studies available for adenine and Chemical Dependence

ArticleYear
Tenofovir helps prevent HIV in drug users.
    BMJ (Clinical research ed.), 2013, Jun-18, Volume: 346

    Topics: Adenine; Anti-HIV Agents; Drug Users; HIV Infections; Humans; Organophosphonates; Substance-Related

2013
The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the community.
    PLoS medicine, 2005, Volume: 2, Issue:10

    Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community Networks; HIV Infections; Human Rights

2005
Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence.
    American journal of medical genetics, 2001, Jan-08, Volume: 105, Issue:1

    Topics: Adenine; Adult; Alcoholism; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to

2001